Roivant Sciences Ltd.

Roivant Sciences Ltd.

38.23
USD
+2.19
(+6.08%)
-0.57EPS
25.58BMarket Cap
Nov 09Next Earn

Roivant Sciences Ltd. Documents

Q4 FY2026 · Presentation

Brepocitinib Program Expansion and Batoclimab Update_vF · 18 pages

Read Roivant Sciences Ltd.'s results firsthand

Preview the first 2 pages of this presentation
Create a free account to start reading

Full documents are included with Professional

Q4 FY2026 documents